TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity
Teresa R. Johnson, Srinivas Rao, Robert A. Seder, Man Chen, Barney S. Graham
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity'. Together they form a unique fingerprint.